Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results
AstraZeneca
Giovanni Scambia; Ricardo Villalobos Valencia; Nicoletta Colombo; David Cibula; Charles A Leath; Mariusz Bidziński; Jae-Weon Kim; Joo Hyun Nam; Radoslaw Madry; Carlos Hernández; Paulo A R Mora; Sang Young Ryu; Mei-Lin Ah-See; Elizabeth S Lowe; Natalia Lukashchuk; Dave Carter; Richard T Penson
Biostatistics, Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.